{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T11:59:48Z","timestamp":1794916788438,"version":"4.9.1"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis Supplements"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.atherosclerosissup.2017.05.034","type":"journal-article","created":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T11:00:40Z","timestamp":1496401240000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["History of lipidology and lipoprotein apheresis"],"prefix":"10.1016","volume":"30","author":[{"given":"Ulrich","family":"Julius","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9438","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosissup.2017.05.034_bib2","article-title":"Deutsche Gesellschaft f\u00fcr Kardiologie \u2013 Herz- und Kreislaufforschung e.V","year":"2015","journal-title":"Deutscher Herzbericht"},{"issue":"5\u20136","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib3","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00103-013-1670-0","article-title":"Prevalence of dyslipidemia among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS 1)","volume":"56","author":"Scheidt-Nave","year":"2013","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"10.1016\/j.atherosclerosissup.2017.05.034_bib4","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s12889-016-2826-2","article-title":"Changes in mean serum lipids among adults in Germany: results from National Health Surveys 1997\u201399 and 2008\u201311","volume":"16","author":"Truthmann","year":"2016","journal-title":"BMC Public Health"},{"issue":"31\u201332","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib5","first-page":"523","article-title":"Familial hypercholesterolemia: developments in diagnosis and treatment","volume":"111","author":"Klose","year":"2014","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.atherosclerosissup.2017.05.034_bib6","unstructured":"Kassen\u00e4rztliche Bundesvereinigung. Qualit\u00e4tsbericht \u2013 Ausgabe 2016 \u2013 Berichtsjahr 2015. Special edition 2015."},{"issue":"23","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib7","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosissup.2017.05.034_bib8","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/BF01949591","article-title":"Ueber die Wirkung der tierischen Eiweisse auf der Aorta","volume":"198","author":"Ignatowski","year":"1909","journal-title":"Virchows Arch Pathol Anat"},{"key":"10.1016\/j.atherosclerosissup.2017.05.034_bib9","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1515\/bchm2.1910.67.2.174","article-title":"Ueber den Gehalt normaler und atheromatoser Aorten an Cholesterol und Cholesterinester","volume":"67","author":"Windaus","year":"1910","journal-title":"Zeitschrift Physiol Chemie"},{"key":"10.1016\/j.atherosclerosissup.2017.05.034_bib10","first-page":"1","article-title":"Ueber experimentelle Cholesterinsteatose und ihre Bedeutung fuer die Entstehung einiger pathologischer Prozesse","volume":"24","author":"Anitschkow","year":"1913","journal-title":"Zentrbl Allg Pathol Pathol Anat"},{"issue":"3","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib11","first-page":"225","article-title":"Experimental atherosclerosis induced by repeated intravenous administration of hypercholesterolaemic serum","volume":"8","author":"Klimov","year":"1966","journal-title":"Cor Vasa"},{"issue":"1\u20133","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0021-9150(85)90051-6","article-title":"Lipoprotein-antibody immune complexes. Their catabolism and role in foam cell formation","volume":"58","author":"Klimov","year":"1985","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosissup.2017.05.034_bib13","doi-asserted-by":"crossref","first-page":"888","DOI":"10.7326\/0003-4819-61-5-888","article-title":"Risk factors in coronary heart disease. An evaluation of several serum lipids as predictors of coronary heart disease; The Framingham Study","volume":"61","author":"Kannel","year":"1964","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib14","first-page":"473","article-title":"Giant molecules and cholesterol in relation to atherosclerosis","volume":"88","author":"Keys","year":"1951","journal-title":"Bull Johns Hopkins Hosp"},{"key":"10.1016\/j.atherosclerosissup.2017.05.034_bib15","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","article-title":"A new serum type system in man\u2013the LP system","volume":"59","author":"Berg","year":"1963","journal-title":"Acta Pathol Microbiol Scand"},{"issue":"14","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib16","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0002-9149(96)00159-2","article-title":"Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men","volume":"77","author":"Assmann","year":"1996","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib17","first-page":"14","article-title":"1985 Nobel laureates in medicine","volume":"44","author":"Brown","year":"1996","journal-title":"J Investig Med"},{"issue":"2","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib18","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"issue":"Suppl. 1","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib19","first-page":"S1","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"217","author":"Catapano","year":"2011","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib20","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","volume":"68","author":"Lloyd-Jones","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib21","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib22","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis","volume":"60","author":"Ference","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"9753","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib23","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib24","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.jacc.2015.02.020","article-title":"Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2\u00a0\u00d7\u00a02 Factorial Mendelian Randomization Study","volume":"65","author":"Ference","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib25","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"issue":"45","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib26","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib27","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1161\/ATVBAHA.114.303462","article-title":"A common LPA null allele associates with lower lipoprotein(a) levels and coronary artery disease risk","volume":"34","author":"Kyriakou","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib28","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1139\/cjpp-2014-0478","article-title":"Niacin as antidyslipidemic drug","volume":"93","author":"Julius","year":"2015","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.atherosclerosissup.2017.05.034_bib29","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-med-050311-163305","article-title":"Future of cholesteryl ester transfer protein inhibitors","volume":"65","author":"Rader","year":"2014","journal-title":"Annu Rev Med"},{"issue":"5","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib30","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4239\/wjd.v7.i5.74","article-title":"Use of fibrates in the metabolic syndrome: a review","volume":"7","author":"Shipman","year":"2016","journal-title":"World J Diabetes"},{"key":"10.1016\/j.atherosclerosissup.2017.05.034_bib31","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.atherosclerosissup.2015.02.005","article-title":"Mipomersen and lomitapide: two new drugs for the treatment of homozygous familial hypercholesterolemia","volume":"18","author":"Gouni-Berthold","year":"2015","journal-title":"Atheroscler Suppl"},{"issue":"11","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib32","doi-asserted-by":"crossref","first-page":"e49006","DOI":"10.1371\/journal.pone.0049006","article-title":"Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy","volume":"7","author":"McGowan","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/M14-2957","article-title":"Effects of proprotein convertase subtilisin\/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis","volume":"163","author":"Navarese","year":"2015","journal-title":"Ann Intern Med"},{"issue":"16","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib34","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosissup.2017.05.034_bib35","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"9860","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib36","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"issue":"32","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib37","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib38","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40265-014-0339-9","article-title":"Alipogene tiparvovec: a review of its use in adults with familial lipoprotein lipase deficiency","volume":"75","author":"Scott","year":"2015","journal-title":"Drugs"},{"issue":"17","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib39","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib40","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.atherosclerosis.2015.09.029","article-title":"Improved cardiovascular outcomes following temporal advances in lipid-lowering therapy in a genetically-characterised cohort of familial hypercholesterolaemia homozygotes","volume":"243","author":"Thompson","year":"2015","journal-title":"Atherosclerosis"},{"issue":"15","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib41","first-page":"1377","article-title":"Homozygous cutaneo-tendinous forms of hypercholesteremic xanthomatosis in an exemplary familial case. Trial of plasmapheresis as heroic treatment","volume":"118","author":"de Gennes","year":"1967","journal-title":"Bull Mem Soc Med Hop Paris"},{"issue":"6","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib42","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/MOL.0000000000000234","article-title":"Lipoprotein apheresis: present and future uses","volume":"26","author":"Moriarty","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.atherosclerosissup.2017.05.034_bib43","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.atherosclerosissup.2015.02.018","article-title":"Effects of different lipoprotein apheresis methods on serum protein levels","volume":"18","author":"Julius","year":"2015","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.atherosclerosissup.2017.05.034_bib44","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.atherosclerosissup.2015.02.028","article-title":"Effects of lipoprotein apheresis on PCSK9 levels","volume":"18","author":"Julius","year":"2015","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.atherosclerosissup.2017.05.034_bib45","first-page":"14486","article-title":"Bekanntmachung des Bundesausschusses der \u00c4rzte und Krankenkassen \u00fcber eine \u00c4nderung der Richtlinien \u00fcber die Bewertung \u00e4rztlicher Untersuchungs- und Behandlungsmethoden gem\u00e4\u00df \u00a7 135 Abs. 1 des F\u00fcnften Buches Sozialgesetzbuch (SGB V) (BUB-Richtlinien)","volume":"123","author":"Bundesministerium f\u00fcr Gesundheit","year":"2003","journal-title":"BAnz"},{"key":"10.1016\/j.atherosclerosissup.2017.05.034_bib46","first-page":"3321","article-title":"Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses \u00fcber eine \u00c4nderung der Richtlinie Methoden vertrags\u00e4rztliche Versorgung: Apherese bei isolierter Lp(a)-Erh\u00f6hung","volume":"138","author":"Bundesministerium f\u00fcr Gesundheit","year":"2008","journal-title":"BAnz"},{"key":"10.1016\/j.atherosclerosissup.2017.05.034_bib47","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3400\/avd.pad.14.01000","article-title":"5(th) Asian PAD Workshop","volume":"7","author":"Lee","year":"2014","journal-title":"Ann Vasc Dis"},{"key":"10.1016\/j.atherosclerosissup.2017.05.034_bib48","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1046\/j.1523-1755.1999.07130.x","article-title":"Low density lipoprotein apheresis therapy for steroid-resistant nephrotic syndrome. Kansai-FGS-Apheresis Treatment (K-FLAT) Study Group","volume":"71","author":"Muso","year":"1999","journal-title":"Kidney Int Suppl"},{"issue":"2","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib49","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1744-9987.2009.00747.x","article-title":"Retrospective analysis of long-term lipid apheresis at a single center","volume":"14","author":"Koziolek","year":"2010","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.atherosclerosissup.2017.05.034_bib50","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.atherosclerosissup.2015.02.034","article-title":"Actual situation of lipoprotein apheresis in Saxony in 2013","volume":"18","author":"Emmrich","year":"2015","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.atherosclerosissup.2017.05.034_bib51","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.atherosclerosissup.2015.02.013","article-title":"Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: findings gathered from more than 36,000 treatments at one center in Germany","volume":"18","author":"Heigl","year":"2015","journal-title":"Atheroscler Suppl"},{"issue":"12","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib52","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0002-9149(98)00692-4","article-title":"Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group","volume":"82","author":"Mabuchi","year":"1998","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib53","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1046\/j.1526-0968.2003.00074.x","article-title":"Long-term effect of low-density lipoprotein apheresis in patients with heterozygous familial hypercholesterolemia","volume":"7","author":"Higashikata","year":"2003","journal-title":"Ther Apher Dial"},{"issue":"10","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib54","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1161\/01.CIR.93.10.1826","article-title":"Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis","volume":"93","author":"Kroon","year":"1996","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib55","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.atherosclerosissup.2012.10.005","article-title":"Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern","volume":"14","author":"von Dryander","year":"2013","journal-title":"Atheroscler Suppl"},{"issue":"3","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib56","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/ncpcardio1456","article-title":"Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events","volume":"6","author":"Jaeger","year":"2009","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"2","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib57","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/aor.12135","article-title":"Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events?","volume":"38","author":"Rosada","year":"2014","journal-title":"Artif Organs"},{"issue":"24","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib58","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","article-title":"Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study","volume":"128","author":"Leebmann","year":"2013","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib59","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1161\/ATVBAHA.116.307983","article-title":"Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 years of follow-up and apolipoprotein(a) characterization","volume":"36","author":"Roeseler","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosissup.2017.05.034_bib60","unstructured":"Kassen\u00e4rztliche Bundesvereinigung. Qualit\u00e4tsbericht \u2013 Ausgabe 2014-Berichtsjahr 2013. Special edition 2014."},{"issue":"5","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib61","doi-asserted-by":"crossref","first-page":"30C","DOI":"10.1016\/0002-9149(84)90854-3","article-title":"Lipid research clinics coronary primary prevention trial: results and implications","volume":"54","author":"Rifkind","year":"1984","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib62","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1194\/jlr.M066399","article-title":"Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results","volume":"57","author":"Yang","year":"2016","journal-title":"J Lipid Res"},{"issue":"10002","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib63","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib64","first-page":"228","article-title":"New class of drugs: therapeutic RNAi inhibition of PCSK9 as a specific LDL-C lowering therapy","volume":"120","author":"Strat","year":"2016","journal-title":"Rev Med Chir Soc Med Nat Iasi"},{"issue":"4","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib65","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/MOL.0000000000000091","article-title":"LDL-cholesterol reduction in patients with hypercholesterolemia by modulation of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase","volume":"25","author":"Filippov","year":"2014","journal-title":"Curr Opin Lipidol"},{"issue":"46","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib66","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1093\/eurheartj\/ehu171","article-title":"Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial","volume":"35","author":"Tardif","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosissup.2017.05.034_bib67","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.atherosclerosis.2016.05.038","article-title":"HDL mimetic CER-001 targets atherosclerotic plaques in patients","volume":"251","author":"Zheng","year":"2016","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.atherosclerosissup.2017.05.034_bib68","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.ahj.2015.01.008","article-title":"The effect of an apolipoprotein A-I-containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: the Modifying Orphan Disease Evaluation (MODE) study","volume":"169","author":"Hovingh","year":"2015","journal-title":"Am Heart J"}],"container-title":["Atherosclerosis Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567568817300764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567568817300764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T01:51:09Z","timestamp":1535766669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567568817300764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":68,"alternative-id":["S1567568817300764"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2017.05.034","relation":{},"ISSN":["1567-5688"],"issn-type":[{"value":"1567-5688","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"History of lipidology and lipoprotein apheresis","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis Supplements","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2017.05.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}